Author index

O. C. Abraham, 130
A.-B. Abudu, 514
A. Adedeji, 573
Z. Aktaş, 499
F. Al-Ali, 261
T. Alarcón, 221
L. Alcalá, 453
B. S. Allen, 671
F. Allerberger, 639
W. Y. Almawi, 688
J. I. Alós, 571
H. Alsoub, 382
M. E. Alvarez, 379
Ö. Anğ, 499
P. Anderson, 666
A. Andreu, 25
J. Anguita, 695, 712
A. I. Anton, 345
P. Appelbaum, 702
G. F. Araj, 498, 510, 517
E. A. Aranda, 167
C. Ardanuy, 32
J. M. Arizón, 367, 399
C. Arnold, 479
O. Aspevall, 173
G. Aubert, 218
V. Ausina, 164

M. Bains, 563, 577
Ç. Bal, 499
L. Baldassarri, 193
S. Ballesta, 65
P. Balvay, 705
S. I. Bandak, 671
F. Baquero, 278, 352, 379
F. Barbut, 405
T. Barfod, 507
A. L. Barry, 93
A. Bartoloni, 48
O. Bauraind, 696
R. Bax, 316
M. L. Beach, 152
N. Beader, 626
B. Bedenić, 626
B. Belian, 572
A. van Belkum, 442
Y. Benito, 36
C. Benoit, 3
P. Berche, 47
K. Bergh, 39
A. W. Berrington, 161
X. Bertrand, 705
D. J. Biedenbach, 397
A. Bilgic, 699
S. Birengel, 514
G. Blair, 421
J. R. Blanco, 637, 655
S. Blanco, 164
M. Blasco-Navalpotro, 273, 285
S. Bobin-Dubreux, 267
M. Bodí, 32
A. Bols, 391
R. A. Bonomo, 708
M. Bonten, 619
M. Boogaerts, 103
E. Bordi, 503
S. Borrás, 273, 285
H. W. Boucher, 17
S. K. Bouchillon, 671
F. Boufidou, 138
P. Bourée, 641
A. Bouvet, 362
E. Bouza, 403 451, 453, 458, 523, 532
N. van den Braak, 442
J. S. Brazier, 404, 428
V. Broc, 362
S. D. Brown, 93
A. G. Buiting, 619
E. Burel, 267
D. Burhanoglu, 699
B. Bussels, 391
R. Bywater, 316

L. Cabero, 25
J. J. Camarena, 273, 285
E. Cambau, 553
A. Campbell, 432
E. Campisi, 48
J. Campos, 287
J. J. Canet, 648
B. Cantinieaux, 277
R. Cantón, 278, 352
J. A. Capdevila, 206
A. Carricajo, 218
H. Carsenti-Etesse, 144
J. L. Casado, 394
M. Casal, 224
P. Cassinotti, 461
D. Castander, 32
J. D. Cavallo, 144
C. Cavusoglu, 699
M. Célard, 36
R. Cevenini, 200
P. Champsaur, 107
P. H. Chandrasekar, 130
S. Chatzipanagiotou, 138
H. Chaudemanche, 275
S. Cherifi, 277
Y. Chong, 88
L. S. Christensen, 507
M. Ciantar, 158
C. Cicek-Saydam, 699
O. Ciofu, 238
G. Claeys, 22, 55
S. C. Clarke, 565
N. Clumeck, 277
F. Çokça, 514
R. Colebunders, 562, 576
P. Colson, 107
T. M. Coque, 278
G. Cornaglia, 316
G. Corti, 48
S. Costa-Oliveira, 609
P. Courvalin, 169
O. Cuevas, 695, 712
B. A. Cunha, 581, 693, 711

F. D'Ambrosio, 503
A. D'Antuono, 200
J. L. Daccache, 688
F. Dalet, 345
R. N. Davidson, 657
T. Davies, 702
T. De Baere, 55
S. De Martino, 96
S. De Wit, 277
J. E. Degener, 51
M. Degré, 254
M. Deighton, 193
M. Del Grosso, 503
M. Delforge, 103
P. Dellamonica, 144
M. Delmée, 411
V. Delorme, 36
D. W. Denning, 11
C. Dhiraputra, 438
N. Dhoyen, 661
E. Diaz, 32
D. J. Diekema, 152
M. P. Dierich, 639
A. Digranes, 238
M. A. Dimopoulos, 100
L. Doganci, 341
J. Domínguez, 164
R. Doria, 387
C. Dos Santos, 114
L. Doutrelant, 275
M. Dupuis, 696
X. Duval, 3

C. Edlund, 230
G. F. S. Edwards, 565
H. Ellerbrok, 120
I. Erdozain, 637, 655
D. Esel, 369, 548
J. Etienne, 36, 267

E. Faggi, 48
X.-G. Fan, 187
A. Ferrara, 114
M. Ferrus, 244
M.-H. Fiévet, 553
R. R. Finan, 688
H. Fiolet, 619
L. Flores De Jacoby, 213
G. Fluge, 238
J. Fortea, 206
J. D. Fox, 179
E. Frau, 641
H. Fredlund, 125
A. Friedrich, 37
P. C. Fuchs, 93
S. J. Furrows, 227

G. Gabriellini, 387
P. Galanaud, 641
N. Galí, 164
L. Gallego, 331
V. Gant, 173
J. Garaizar, 331
J. Garau, 648
I. García, 65
J. M. García-Lechuz Moya, 84
J. M. García-Lechuz, 337, 343, 453
E. Garrabé, 144
P. Gastmeier, 521
V. Gauduchon, 36
J. Gavaldà, 206
F. Gavilán, 367, 399
A. Gelosia, 193
S. Genç, 372
G. Gergova, 42
H. Giamarellou, 70
J. Gibson, 244

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

M. Giménez, 164
P. Girardo, 267
M. Gniadkowski, 597
S. Gökahmetoglu, 369
J. L. Gómez-Garcés, 571
X. Gomis, 206
N. Gönüllü, 499
M. J. González-Beato, 337, 343
J. González-Lahoz, 678
H. Goossens, 316
B. Gordts, 391
F. K. Gould, 161
G. C. Gray, 397
K. Grenet, 553
N. Grude, 543
M. Guibert, 641
D. Gür, 470
C. Gutierrez, 637, 655

O. C. Haanaes, 238
H. Hallander, 173
J. M. T. Hamilton-Miller, 339
T. K. Held, 120
P. Hermans, 277
J. L. Hernández, 567
S. Hernangómez, 453
C. S Higgins, 308
S. Hilmioglu, 699
S. J. Hiom, 308
P. R. Hira, 261
D. J. Hoban, 671
D. Hoellman, 702
B. Hoen, 275
N. Høiby, 238, 651
H. Holmberg, 492
E. Holter, 254
H. van Hooff, 619
G.-L. Hu, 187
E. Hunstad, 238
P. Hunter, 316
S. Huttayananont, 438
G.-Y. Hwang, 104
S.-O. Hwang, 104

J. Iqbal, 261
N. Irani-Hakime, 688
D. Irwin, 666
V. Isham, 316

M. Jacobs, 702
M. R. Jacobs, 589
I.-H. Jang, 104
K. Janitschke, 120
A. R. Jansz, 486
V. Jarlier, 316, 553
S. Jarraud, 267
B. Jaulhac, 96
M. R. Javier, 224
F. Jehl, 661
S. H. Jeong, 98
I. Jiménez-Nácher, 678
H. K. Johansen, 651
R. Jones, 316
R. N. Jones, 152, 397
M. Jordán, 273, 285

S. Kalich, 376
S. S. Kanj, 498, 510, 517
M. E. Kaufmann, 573
E. Kavouklis, 70
P. Kerhli, 96
J. R. Kerr, 573
E. Keuleyan, 42
M. C. Keven, 514
R. R. Khalifeh, 498, 517
D. Kiliç, 341
Y. A. Kim, 88
J. M. Kindelán, 224
J. W. Kislak, 17
K. Kjeldsen, 651
N. Kleinkauf, 326
K. Klemm, 28
J. Kluytmans, 523, 532
S. Kocagöz, 548
S. Kolmannskog, 39
K. Kontoghiorgi, 70
E. Kostis, 100
T. Kouri, 173
P. Kragsbjerg, 125
B.-E. Kristiansen, 543, 682
K. I. Kristiansen, 254
D. Krüger, 120
A. Kulkarni, 179
O. Kupferschmidt, 120

M. Łuczak, 442
B. La Scola, 75, 107
M. Labetoulle, 641
V. J. LaBombardi, 17
S. Ladhani, 301
Å. Lagergren, 447
R. Lama, 367, 399
A. Lamikanra, 514
J. M. Lazar, 693, 711
K. Lee, 88
K. J. Lee, 98
S. H. Lee, 98
W. van Leeuwen, 442
J. N. Legakis, 138
C. Leport, 3
D. Levy, 47
T.-G. Li, 187
S. Lightman, 636, 653
G. Lina, 267
M. J. Linares, 224
L. Linger, 661
L. Liu, 187
S.-H. Liu, 187
D. Loebenberg, 339
C. M. Longshaw, 385
P. Longuet, 3
P. López, 206
M. López-Brea, 221
S. López-Hernández, 221
F. López-Rubio, 367, 399
R. López-Vélez, 291, 394
A. M. Lovering, 666
E. Loza, 352
G. S. Lucas, 573
B. Lund, 230
A. Lundberg, 447
Y. Lundgren, 230
A. Lupi, 114
V. Luyasu, 696
W. A. Lynn, 636, 653

A. P. MacGowan, 666
C. R. Madeley, 171
T. V. Madsen, 507
J. Maertens, 103
E. K. Manavathu, 130
O. Manzor, 572
B. Maraha, 619
A. Marangoni, 200
F. Marín, 645
N. Markova, 358
R. Markovska, 42
J. C. Martín, 678
M. T. Martin, 206
P. Martínez, 678
J. Martinez-de-Oliveira, 609
A. J. Martinez-Murcia, 345
P. Martino, 37
M. Martinot, 96
G. Martirosian, 442
L. Matas, 164
J. McCoubrey, 421
F. Meisel-Mikołajczyk, 442
F. Menichetti, 387
B. Merad, 362
F. Messina, 387
P. Miailhes, 641
P. Michielsen, 562, 576
A. Micozzi, 37
H. Mieszczanska, 693, 711
G. H. Miller, 470
R. C. Moellering, 17
M. Monaco, 37
H. Monteil, 96, 661
R. Moog, 96
C. B. Moore, 11
M. Y. Mooty, 498, 517
A. Morales, 645
L. Mortensen, 682
C. Mouren, 36
J. W. Mouton, 486
S. Mullier, 696
P. Muñoz, 451, 458, 523, 532, 695, 712
V. Murbach, 661
S. M. Murtough, 308
R. Mutters, 213

T. Naas, 641
K. Nagi, 702
M. Negosanti, 200
H. N. Newman, 158
T. van Nguyen, 193
C. Nicolaou, 138
I. Nilsson-Ehle, 376
C. Nonnenmacher, 213
C. E. Nord, 230, 376
K. P. Nordal, 254
P. Nordmann, 641
E. Nulens, 391

K. L. Oakley, 11
P. Obuch-Woszczatyński, 442
H. R. Ochs, 376
I. Odenholt, 376
B. Ojeniyi, 238
I. N. Okeke, 514
A. Oliver, 278
M. Olona, 32
M. Olsson, 492
P. Orozova, 358
J. Oteo, 571
J. A. Oteo, 637, 655
U. Över, 470
R. J. Owen, 244
N. Ozkalay, 699

X. Pagerols, 648
A. Pahissa, 206
J. Palomo, 451, 458
A. Pantosti, 503
C. Papadimitriou, 100
V. Papastamopoulos, 3
H.-C. Park, 104
J.-S. Park, 104
P. Parola, 80
Á. Pascual, 65

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 715–717

D. L. Paterson, 708
C. Patry, 705
J. Pawlak, 572
D. J. Payne, 308
Y. Péan, 553
N. Pechier, 275
P. Pedroso, 164
W. E. Peetermans, 388
T. Peláez, 453
E. J. Perea, 65
J. Pérez, 645
C. Perronne, 3
J. D. Perry, 161
O. Péter, 461
J.-C. Petit, 405
V. Petrocheilou-Paschou, 100
V. Petroyianni, 138
M. A. Pfaller, 152
R. Philip, 261
J. Philippe-Bert, 36
I. Phillips, 51, 316
Y. Piemont, 96
C. Pina-Vaz, 609
G. Pini, 48
V. Pintado, 291, 394
H. Pituch, 442
P. Plesiat, 144
B. Polsky, 563, 577
P. Pongpech, 438
I. R. Poxton, 421
J. Prag, 34
C. Prat, 164
H. Prifti, 100
S. D. Putnam, 397

G. Quindós, 331

T. Radoucheva, 358
C. Ramos, 567
G. G. Rao, 25
D. Raoult, 75, 80
J. Reid, 565
L. B. Reller, 510
J. Rello, 32
A. Rementeria, 331
M. E. Reverdy, 267
J. C. Ricaurte, 17
L. B. Rice, 708
G. L. Ridgway, 227
B. J. A. Rijnders, 388
J. Robert, 553
A. C. Rodloff, 326
A. G. Rodrigues, 609
F. Rodríguez, 224
F. Rodríguez-Gómez, 695, 712
F. Rodriguez-Valera, 345
P. M. Roger, 144
H. Rollag, 254
M. de la Rosa Fraile, 25
H. Rostane, 362
J. Ruiz, 645
M. Rupnik, 417
A. D. Russell, 308
B. Rynnel-Dagöö, 230

M. Sabrià, 164
A. Safdar, 563, 577
D. Sahm, 316
S. A. Salamon, 34
J. Salcedo, 637, 655
M. Şalcioğlu, 499
V. Sambri, 200
R. San Juan, 453, 523, 532
B. Sánchez del Saz, 352
C. Sánchez, 648
M. A. Sánchez, 352
P. Sánchez-Guijo, 367, 399
A. Sánchez-Sousa, 379
R. A. Sandnes, 682
J. A. T. Sandoe, 385
F. Sansonetty, 609
E. Sanz, 645
L. Saravolatz, 572
M. S. Sartini, 387
P. Sawanpanyalert, 438
M. Sayan, 372
L. Schlegel, 362
P. E. Schoch, 693, 711
M. Schwaiger, 461
F. Scott, 479
A. Scotto d'abusco, 503
E. Selbs, 693, 711
S. Senn, 316
S. Shah, 339
H. E. Sharide, 688
H. B. Shin, 88
W. Siegert, 120
E. Simarro, 645
M. A. Simone, 200
M. T. Simonetti, 48
P. G. Skogen, 39
M. Socan, 91
F. Solís, 224
N. Sopena, 164
V. Soriano, 678
D. A. Spratt, 158
S. Stamatelopoulos, 100
J. Stanley, 479
J. M. Starr, 432
J. Sterner, 230
E. E. Stobberingh, 619
O.-T. Storrøsten, 238
K. Strålin, 492
T. Strateva, 42
M. Struelens, 316
C. P. K. Subudhi, 573
B. Sümerkan, 369, 548
B. Svenungsson, 447

A. Taher, 510
D. Talon, 705
H. Tamim, 688
D.-M. Tan, 187
A. Tarasi, 37
D. Tarragó, 379
C. Tascini, 387
C. Tavares, 609
D. Taylor, 316
M. Temmerman, 22
L. Thom, 565
M. Thouverez, 705
J. Threlfall, 479
H. Tomaso, 639
J. Torre-Cisneros, 224, 367, 399
E. Tortoli, 48
M. M. Traczewski, 93
H. Tronel, 275
D. Trystram, 553
N. Tulek, 341
G. Tuncer, 341
G. S. Turett, 17
M. R. Turnak, 671
Y. Tveten, 543, 682

E. S. Uçan, 372
Y. Uh, 104
S. Ünal, 470
F. Urbano, 396
P. Urbano, 396

J. Van Eldere, 388
H. W. Van Landuyt, 391
E. Van Wijngaerden, 388
P. Vandenberghe, 103
F. Vandenesch, 36, 267
M. Vaneechoutte, 55
H. Vanpoucke, 55
C. Varela, 278
J. Velasco, 379
M. Venditti, 37
J. Verhaegen, 103
R. Vermesch, 218
G. Verschraegen, 22, 55
J. L. Vildé, 3
J. L. Villanueva, 224
M. J. Villanueva, 337, 343
P. Vives, 648
M. A. Vizcaíno, 367, 399
F. Vogel, 376
L. Vorland, 682
A. Voss, 523, 532
D. Voutsinas, 70
P. Voutsinas, 70

R. A. Wall, 657
T. R. Walsh, 308
D. Westmoreland, 179
K. Wettich, 376
A. White, 316
E. Williamson, 308
A. Willke, 341
M. Wilson, 158
R. Wise, 1
S. Wongwanich, 438

J. Yakoob, 187
J. Yáñez, 451, 458
H.-X. Yang, 187
K.-J. Yoon, 104
A. Yüce, 372
M. Yücesoy, 372
J. H. Yum, 88

M. Zabalza, 637, 655
Ż. Żagar, 626
Z. Zhang, 187
Ziha-Zarifi, 144

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 715–717

Subject index

Abscess, pyogenic hepatic (concise communication), 567
Acetazolamide, effect on β-lactam aqueous humor kinetics, 70
Acineteobacter baumannii complex, cephalosporinases from (concise communication), 221
Acinetobacter spp., metallo-β-lactamase-producing, modified Hodge and EDTA-disk synergy tests (concise communication), 88
AIDS (acquired immunodeficiency syndrome)
  histoplasmosis, late diagnosis (correspondence), 48
  nodular hepatic lesions in AIDS patient (continuing medical education), 562/576
  primary effusion lymphoma, acute pulmonary hypertension following paclitazel (concise communication), 277
Aminoglycoside resistance mechanisms, 470
Amoxycillin–clavulanate, otitis media, ecological effects on normal microflora, 230
Amphotericin B, susceptibility of voriconazole-resistant *Aspergillus fumigatus*, 130
Amplified fragment length polymorphism (AFLP) genotyping, metronidazole-resistant *Helicobacter pylori*, 244
Antibiotic therapy
  antibiotic-containing bead chains, chronic bone infections, 28
  optimisation using pharmacokinetic and pharmacodynamic parameters (review), 589
Antibiotics
  animal growth promotion (correspondence), 169
  β-lactam
    effect of acetazolamide on kinetics in aqueous humor, 70
    Pseudomonas aeruginosa resistance and, 144
  respiratory disease, effect on bactericidal activity of some fractions of alveolar surfactant, 114
Antifungal suscebtibility testing, *Candida* strains, 609
Antigen testing, urinary, meningococcal disease (concise communication), 565
Antimicrobial resistance
  aminoglycoside resistance mechanisms, 470
  antibiotic and biocide resistance among non-fermenting Gram-negative bacteria, 308
  Streptococcus pneumoniae, nasopharyngeal carriage of resistant strains (concise communication), 42
  surveillance, 316
  viridans group streptococci, 152
Antimicrobial susceptibility
  bacterial respiratory pathogens in Norway, 682
  clinical isolates of *Haemophilus influenzae* and *Moraxella catarrhalis*, 671
  non-fermenting Gram-negative bacteria, 308
  Pseudomonas aeruginosa in intensive care unit (concise communication), 705
  Salmonella and *Shigella* strains in Turkey (concise communication), 341
  test breakpoints of national societies (notes and comments), 51
  voriconazole-resistant *Aspergillus fumigatus*, 130
Antimicrobial susceptibility testing
  cefditoren, quality control parameters (concise communication), 93
  ceftibuten disk diffusion susceptibility tests, 326
  evaluation of OSIRIS video reader disk diffusion test reading, 352
Antiretroviral therapy, highly active *see* Highly active antiretroviral therapy
Aspergillus fumigatus, voriconazole-resistant, 130
Azithromycin, use in healthy adults (correspondence), 396, 397
Aztreonam, effect on β-lactam aqueous humor kinetics, 70

Bartonella henselae neuroretinitis (concise communication), 387
Beta-lactamases
  extended-spectrum (ESBLs)
    evolution and epidemiology of ESBLs and ESBL-producing microorganisms (review), 597
    evolution of TEM β-lactamase genes (concise communication), 98
    extraction and analysis from clinical strains of *Klebsiella pneumoniae* (concise communication), 708
    prevalence in group-1 β-lactamase-producing isolates (concise communication), 278
    production rates of *Salmonella* and *Shigella* strains in Turkey (correspondence), 341
    SHV-producing klebsiellae, antibacterial activity of cefpirome and cefepime, 626
  modified Hodge and EDTA-disk synergy tests for screening of metallo-β-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* (concise communication), 88
  post-β-lactamase-inhibitor effect of clavulanic acid against *Klebsiella pneumoniae* and *Haemophilus influenzae*, 661
Beta-lactams *see* Antibiotics, β-lactam; Cephalosporins
Blood transfusion: properties of *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* in red blood cell concentrate of different ABO groups during storage, 358
Bone infections, chronic, treatment with gentamicin PMMA chains, 28
Borrelia burgdorferi infection(s)
  anti-*Borrelia burgdorferi* immunoglobulin G seroconversion caused by administration of intravenous gammaglobulins (concise communication), 696
  diagnosis using real-time PCR assay, 461
Borrelial diseases, emergence in Europe, 80
Bronchiolitis obliterans organizing pneumonia (continuing medical education), 399
Brucella
  BacT/Alert blood culture system (concise communication), 369

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

infective endocarditis (concise communication), 382
neurobrucellosis (continuing medical education), 517

Campylobacter fetus pericarditis in patient with β-thalassemia (concise communication), 510
Campylobacter lari bacteremia (concise communication), 96
Candida spp.
adherence to polystyrene (concise communication), 379
cytometric evaluation of susceptibility to antifungals, 609
LY303366 activity against, 11
Candida dubliniensis septic thrombophlebitis (continuing medical education), 273/285
Candidiasis, heroin addicts, detection of antibodies to *Candida albicans* germ tubes (concise communication), 224
Capnocytophaga spp., culture media (concise communication), 158
Catheter-related infection
Chryseobacterium indologenes bacteremia in oncology patient (concise communication), 391
Ewingella americana bacteremia (correspondence), 103
polyclonal, *Staphylococcus epidermis* (concise communication), 388
Staphylococcus aureus, antimicrobial activity of sodium heparin using antibiotic-lock technique, 206
Cefditoren susceptibility tests, quality control parameters (concise communication), 93
Cefepime, antibacterial activity against *Klebsiella pneumoniae* strains producing SHV extended-spectrum β-lactamases, 626
Cefotaxime, effect on β-lactam aqueous humor kinetics, 70
Cefpirome, antibacterial activity against *Klebsiella pneumoniae* strains producing SHV extended-spectrum β-lactamases, 626
Cefpirome–vancomycin, methicillin-resistant *Staphylcoccus aureus* (concise communication), 218
Ceftazidime, effect on β-lactam aqueous humor kinetics, 70
Ceftibuten disk diffusion susceptibility tests according to DIN 58 940 method, 326
Ceftriaxone
effect on β-lactam aqueous humor kinetics, 70
effect on intestinal microflora of step-down therapy of ceftriaxone plus loracarbef versus parenteral ceftriaxone in patients with community-acquired pneumonia (concise communication), 376
Cefuroxime, otitis media, ecological effects on normal microflora, 230
Cephalosporinases, *Acinetobacter baumannii* complex (concise communication), 221
Cephalosporins
effect on β-lactam aqueous humor kinetics, 70
Pseudomonas aeruginosa resistance and, 144
Cervical intraepithelial neoplasia, human papillomavirus detection in cervico-vaginal scrapes, 688
Chest wall infection following reconstructive surgery in lung cancer patient (continuing medical education), 563/577
Chloramphenicol, vancomycin-resistant *Enterococcus faecium* bacteremia, 17
Chryseobacterium indologenes bacteremia in oncology patient with totally implanted intravascular device (concise communication), 391
Clavulanic acid, post-β-lactamase-inhibitor effect against *Klebsiella pneumoniae* and *Haemophilus influenzae*, 661
Clostridium difficile
assays for detection of toxin and/or antigen in stool specimens, 55
characteristics of strains from asymptomatic individuals and from diarrheal patients, 438
clonal dissemination of toxin-A negative/toxin-B-positive strain in Poland, 442
cytotoxin B in adults with diarrhea, 447
infections
diagnosis, 411
epidemiology, 405, 432
extra-intestinal (concise communication), 453
mathematical modeling, 432
pathogenicity, 421
typing, 428
detection of variant strains in routine laboratory, 417
Continuing medical education
chest wall infection following reconstructive surgery in lung
cancer patient, 563/577
endocardial vegetation, 693/711
group A streptococcal gangrene, 84
headache and diplopia, 498/517
heart transplant recipient with diarrhea and abdominal pain, 451/458
nodular hepatic lesions in AIDS patients, 562/576
penile ulcer and lung infiltrates in leukemic patient, 695/712
poor radiologic evolution of pulmonary tuberculosis in heart transplant patient, 367/399
septic shock in patient with multiple episodes of fever, abdominal pain and leg inflammation, 337/343
sore throat and painful bilateral cervical lymph nodes, 637/654
thermointolerant microorganism growth in blood cultures and catheter tip, 273/285
visual problems in HIV-positive patient, 636/653
Coxiella burnetii, survival within free-living *Acanthamoeba castellanii*, 75
Cryptosporidiosis, seasonality and endemicity in Kuwaiti children, 261
Cystic fibrosis, typing of *Pseudomoas aeruginosa* strains, 238
Cytomegalovirus (CMV)
molecular assays in immunosuppressed transplant recipients, 179
relation of pp67-mRNA and pp65 antigenemia to human CMV disease, 254

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 718–723

Diarrhea
Clostridium difficile, 458
clonal dissemination of toxin-A-negative/toxin-B-positive strain in Poland, 442
cytotoxin B in, 447
diagnosis, 411
epidemiology, 405
strains from diarrheal patients, 438
heart transplant recipient (continuing medical education), 451/458
Diplopia and headache (continuing medical education), 498/517
DNA, polymorphism patterns' analysis, comparison of commercial software packages, 331

Echinocandins: LY303366 activity against *Candida* spp., 11
Ecological effects on normal microflora of cefuroxime and amoxycillin–clavulanate for treatment of otitis media, 230
Education, continuing *see* Continuing medical education
Ehrlichiosis, human granulocytic, Europe, 80
Elderly, pneumonia in (review), 581
Emerging infections, coordinated European approach (editorial), 1
Endocarditis, infective
Brucella (concise communication), 382
Neisseria mucosa, after tongue piercing (concise communication), 275
Pseudomonas mendocina, patient with situs inversus (correspondence), 650
Streptococcus bovis, 3
Streptococcus mutans, molecular diagnosis of recurrent disease by PCR amplification and sequencing (concise communication), 36
subacute (continuing medical education), 693/711
Endophthalmitis, endogenous, and visual loss in HIV-infected patient (concise communication), 641
Enterococcus faecium bacteremia, vancomycin-resistant, chlormaphenicol treatment, 17
Enzyme immunoassay, tuberculosis serodiagnosis, using A60 antigen (concise communication), 372
Enzyme-linked immunosorbent assay (ELISA), syphilis diagnosis, 200
Epidemiology
Clostridium difficile-associated infections, 405
mathematical modeling, 432
penicillin resistance in *Streptococcus pneumoniae*, 548
Erythrovirus B19 urinary tract infection in HIV-positive patient (concise communication), 507
Escherichia coli, pyelonephritogenic strains, ribosomal RNA operons, 345
Evernimicin, pneumococcus' susceptibility to (concise communication), 339
Ewingella americana bacteremia, catheter-related (correspondence), 103

Fluorescent amplified fragment length polymorphism (FAFLP) genotyping, *Salmonella* Enteritidis, 479
Fluoroquinolones, antimicrobial activity against *Streptococcus pneumoniae* (correspondence), 572
Fusidic acid, *Mycobacterium tuberculosis* susceptibility in vitro (concise communication), 699

Gangrene, group A streptococcal (continuing medical education), 84
Gastroenteritis
acute, Niger State, Nigeria (correspondence), 514
Vibrio alginolyticus (correspondence), 104
Gemifloxacin, in vitro activity (concise communication), 499
Gentamicin polymethylmethacrylate chains, chronic osteomyelitis, 28
Glycopeptides, *Staphylococcus aureus* reduced susceptibility, 267
Gram-negative bacteria
aminoglycoside resistance, 470
non-fermenting, antibiotic and biocide resistance, 308
Growth promotion in animals, antibiotics and (correspondence), 169

HAART *see* Highly active antiretroviral therapy
Haemophilus aphrophilus, vertebral infections, 107
Haemophilus influenzae (editorial), 287
antimicrobial susceptibilities of clinical isolates, 671
post-β-lactamase-inhibitor effect of clavulanic acid, 661
Streptococcus pneumoniae and, mixed bacteremic pneumonia (correspondence), 570
Headache and diplopia (continuing medical education), 498/517
Heart transplant patient
diarrhea and abdominal pain (continuing medical education) 451/458
tuberculosis, poor radiologic evolution (continuing medical education), 367/399
Helicobacter pylori
metronidazole-resistant, amplified fragment length polymorphism genotyping, 244
polycolonization among Chinese subjects, 187
Helminthic infestations, Tyrol, Austria (concise communication), 639
Heparin, sodium *see* Sodium heparin
Hepatic abscess, pyogenic (concise communication), 567
Hepatic lesions, nodular, AIDS patient (continuing medical education), 562/576
Heroin addicts, candidiasis, detection of antibodies to *Candida albicans* germ tubes (concise communication), 224
Highly active antiretroviral therapy (HAART)
assessment of benefit, CD4 counts and plasma viremia, 678
effect on visceral leishmaniasis epidemic in HIV-infected patients (correspondence), 394
Histoplasmosis, late diagnosis in AIDS patient (correspondence), 48
HMR 33647, uptake and intracellular activity in phagocytic and non-phagocytic cells, 65

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 718–723

Human immunodeficiency virus (HIV)
erythrovirus B19 urinary tract infection in HIV-positive patient (concise communication), 507
visceral leishmaniasis and (review), 291
decline after introduction of highly active antiretroviral therapy (correspondence), 394
visual problems in HIV-positive patient (continuing medical education) 636/653
endogenous endophthalmitis and (concise communication), 641
Human papillomavirus (HPV), detection in cervico-vaginal scrapes, 688

Immunofluorescence, detection of *Pneumocystis carinii* pneumonia, 492
β2-Integrin expression, effects of *Streptococcus pneumoniae* and tumor necrosis factor-α, 125
Intestinal microflora, effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral ceftriaxone in patients with community-acquired pneumonia (concise communication), 376
Itraconazole, voriconazole-resistant *Aspergillus fumigatus*, 130

Ketolides: HMR 33647 uptake and intracellular activity in phagocytic and non-phagocytic cells, 65
Klebsiella pneumoniae
antibacterial activity of cefpirome and cefepime against strains producing SHV extended-spectrum β-lactamases, 626
extended-spectrum β-lactamases, rapid method of extraction and analysis (concise communication), 708
post-β-lactamase-inhibitor effect of clavulanic acid, 661

Laboratories, good practice in laboratories using nucleic acid amplification methods (editorial), 227
Leishmaniasis, visceral, HIV-associated (review), 291
decline following introduction of highly active antiretroviral therapy (correspondence), 394
Leukemia, chronic myeloid
fatal *Roseomonas gilardii* infection (correspondence), 573
penile ulcer and lung infiltrates in (continuing medical education), 695/712
Levofloxacin, tularemia (correspondence), 167
Linezolid
breakpoints, 283
in vitro evaluation, 486
LY303366, in vitro activity against *Candida* spp. and comparison with other untifungal agents, 11
Lymphoma, primary effusion, AIDS-related, acute pulmonary hypertension following paclitaxel treatment (concise communication), 277

Meningitis, *Stomatococcus mucilaginosus*, in neutropenic child (concise communication), 39
Meningococcal disease, confirmation by urinary antigen testing (concise communication), 565
Methicillin-resistant *Staphylococcus aureus* (MRSA), combined cefpirome and vancomycin (concise communication), 218
Midecamycin diacetate, activity against *Streptococcus pyogenes*, 362
Moraxella catarrhalis, antimicrobial susceptibilities of clinical isolates, 671
Moxifloxacin
bactericidal activity against pneumococci (correspondence), 47
bactericidal activity against *Staphylococcus aureus*, 161
in vitro activity against *Stenotrophomonas maltophilia* blood isolates from patients with hematologic malignancies (concise communication), 37
Mycobacterium tuberculosis, in vitro susceptibility to fusidic acid (concise communication), 699

Neisseria mucosa endocarditis after tongue piercing (concise communication), 275
Neurobrucellosis (continuing medical education), 517
Neuroretinitis, *Bartonella henselae* (concise communication), 387
Neutrophils, oxidative burst, effects of *Streptococcus pneumoniae* and tumor necrosis factor-α, 125
Nosocomial infections
Clostridium difficile, 405
urinary tract (editorial), 521
ESCMID Study Group reports, 523, 532
incidence, clinical characteristics and outcome (ESGNI-004 study), 532
microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study), 523
Nucleic acid amplification methods, good laboratory practice and (editorial), 227
Nucleic acid sequence-based amplification (NASBA), cytomegalovirus infection and disease, 179

Oropharyngeal tularemia (continuing medical education), 637/654
Osteomyelitis
chronic, treatment with gentamicin PMMA chains, 28
vertebral, *Haemophilus aphrophilus* and, 107
Otitis media, comparison of ecological effects on normal microflora of cefuroxime and amoxycillin–clavulanate treatment, 230

Paclitaxel, AIDS-related primary effusion lymphoma, acute pulmonary hypertension following (concise communication), 277
Parvovirus B19 *see* Erythrovirus B19
Penicillin resistance, *Streptococcus pneumoniae*, epidemiology, 548
Penile ulcer and lung infiltrates in leukemic patient (continuing medical education), 695/712
Pericarditis, *Campylobacter fetus*, in patient with β-thalassemia (concise communication), 510

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 718–723

Periodontitis, microbiological characteristics of subgingival microbiota, 213
Pharmacokinetics and pharmacodynamics, optimisation of antimicrobial therapy (review), 589
Phospholipids, effect on bactericidal activity of antimicrobials against respiratory pathogens, 114
Pneumococcus *see Streptococcus pneumoniae*
Pneumocystis carinii pneumonia, detection by polymerase chain reaction and immunofluorescence, 492
Pneumonia
  bronchiolitis obliterans organizing (continuing medical education), 399
  community-acquired, effect on intestinal microflora of step-down therapy of ceftriaxone plus loracarbef versus parenteral ceftriaxone (concise communication), 376
  in elderly (review), 581
  mixed bacteremic, *Streptococcus pneumoniae* and *Haemophilus influenzae* (correspondence), 571
  Pneumocystis carinii, detection by polymerase chain reaction and immunofluorescence, 492
  ventilator-associated, Tarragona treatment strategy, 32
Poliomyelitis eradication, 171
Polymerase chain reaction (PCR)
  Borrelia burgdorferi diagnosis, 461
  cytomegalovirus infection and disease assessment, 179
  human papillomavirus detection in cervico-vaginal scrapes, 688
  Pneumocystis carinii pneumonia detection, 492
  Streptococcus mutans endocarditis diagnosis (concise communication), 36
  Streptococcus pneumoniae DNA detection in serum samples (concise communication), 164
  Toxoplasma gondii DNA detection in human body fluids, 120
  urinary, meningococcal disease (concise communication), 565
Polystyrene, adherence of *Candida* species to (concise communication), 379
Posaconazole, voriconazole-resistant *Aspergillus fumigatus*, 130
Pregnancy, group B streptococcus carriage, detection using modified Granada Agar Medium, 22
Pseudomonas spp., metallo-β-lactamase-producing, modified Hodge and EDTA-disk synergy tests (concise communication), 88
Pseudomonas aeruginosa
  antibiotic susceptibility and genotypic characterization, intensive care unit (concise communication), 705
  resistance, β-lactam antibiotics and, 144
  typing, cystic fibrosis patients, 238
Pseudomonas mendocina, chronic infective endocarditis in patient with situs inversus (correspondence), 650
Pyelonephritis, *Escherichia coli*, ribosomal RNA operons, 345
Pyogenic hepatic abscess (concise communication), 567

Quinolones
  Enterobacteriaceae susceptibility/resistance, 553
  in vitro activities (concise communication), 499
Quinopristin–dalfopristin activity in invasive isolates of *Streptococcus pneumoniae* (concise communication), 503

Renal transplant recipients
  cytomegalovirus infection, pp67-mRNA and pp65 antigenemia and, 254
  infectious complications and antibiotic use, 619
Respiratory diseases
  effect of some fractions of alveolar surfactant on bactericidal activity of different antimicrobials, 114
  epidemiology and resource utilization for patients hospitalized for lower respiratory tract infections, 666
Respiratory pathogens, antibiotic resistance/susceptibility, Norway, 682
Retinitis: *Bartonella henselae* neuroretinitis (concise communication), 387
Rhodotorula septicemia (concise communication), 100
Rickettsial diseases, emergence in Europe, 80
Roseomonas gilardii, fatal infection in patient with refractory blast crisis of chronic myeloid leukemia (correspondence), 573

Salmonella
  antimicrobial susceptibilities and ESBL production rates, Turkey (correspondence), 341
  Enteritidis, fluorescent amplified fragment length polymorphism genotyping, 479
Salmonella panama, superficial septic thrombophlebitis in varicose vein (concise communication), 34
Scedosporium apiospermum, lymphocutaneous syndrome (correspondence), 640
Scedosporium prolificans fungemia (concise communication), 645
Septic shock (continuing medical education), 337/343
Shigella, antimicrobial susceptibilities and ESBL production rates, Turkey, 341
Sodium heparin, antimicrobial activity for treating catheter-related *Staphylococcus aureus* infection using antibiotic-lock technique, 206
SP-A protein, effect on bactericidal activity of antimicrobials against respiratory pathogens, 114
Spleen: prevention and management of infections in patients without spleen, 657
Staphylococcal scalded skin syndrome (review), 301
Staphylococcus aureus
  bactericidal activity of moxifloxacin (concise communication), 161
  cather-related infection, sodium heparin treatment using antibiotic-lock technique, 206
  methicillin-resistant, combined cefpirome and vancomycin (concise communication), 218
  with reduced susceptibility to glycopeptides, 267
  staphylococcal scalded skin syndrome (review), 301

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 718–723

Staphylococcus epidermis
phenotypic and genotypic markers of virulence, 193
polyclonal catheter-related infections (concise communication), 388
Staphylococcus lugdunensis, ventriculoperitoneal shunt infection (concise communication), 385
Statistical analysis, *Clostridium difficile* infection, 432
Stenotrophomonas maltophilia, moxifloxacin activity against blood isolates from patients with hematologic malignancies (concise communication), 37
Stomatococcus mucilaginosus meningitis in neutropenic child, antibiotic treatment (concise communication), 39
Streptococci
group A, gangrene (continuing medical education), 84
group B
detection in pregnant women using modified Granada Agar Medium, 22
prevention of neonatal disease, 25
viridans, antimicrobial resistance, 152
Streptococcus bovis endocarditis, 3
Streptococcus mutans recurrent endocarditis, molecular diagnosis by PCR amplification and sequencing (concise communication), 36
Streptococcus pneumoniae
antimicrobial activity of BMS 284756 and seven fluoroquinolones, (correspondence), 572
DNA, PCR detection in serum samples (concise communication), 164
effects on neutrophil oxidative burst and β2-integrin expression, 125
Haemophilus influenzae and, mixed bacteremic pneumonia (correspondence), 570
moxifloxacin bactericidal activity (concise communication), 47
nasopharyngeal carriage of penicillin-, macrolide- and multiply-resistant strains (concise communication), 42
penicillin resistance, epidemiology, 548
quinolone-resistant, telithromycin activity against (concise communication), 702
susceptibility to evernimicin (concise communication), 339
susceptibility to quinopristin–dalfopristin (concise communication), 503
Streptococcus pyogenes, activity of midecamycin diacetate against, 362
Surfactant, alveolar, effect on bactericidal activity of antimicrobials against respiratory pathogens, 114
Syphilis diagnosis, enzyme-linked immunosorbent assay (recomWell Treponema), 200

Telithromycin, activity against quinolone-resistant pneumococci (concise communication), 702
Thalassemia, *Campylobacter fetus* pericarditis and (concise communication), 510
Thrombophlebitis, septic
Candida dubliniensis (continuing medical education), 273/285
Salmonella panama as cause of superficial disease in varicose vein (concise communication), 34
Thyroid gland, tuberculosis (correspondence), 514
Thyroiditis, Hashimoto's, *Yersinia* plasmid-encoded outer protein antibodies, 138
Tick-borne bacterial diseases emerging in Europe, 80
Tongue piercing, *Neisseria mucosa* endocarditis after (concise communication), 275
Toxoplasma chorioretinitis (continuing medical education), 653
Toxoplasma gondii DNA, detection in human body fluids, 120
Transplant recipients
cytomegalovirus infection
molecular-based assessment strategies, 179
pp67-mRNA and pp65 antigenemia and, 254
diarrhea and abdominal pain (continuing medical education), 451/458
infectious complications and antibiotic use in renal transplant patients, 619
poor radiologic evolution of pulmonary tuberculosis (continuing medical education), 367/399
Tuberculosis
heart transplant patient, poor radiologic evolution (continuing medical education), 367/399
serodiagnosis by enzyme immunoassay using A60 antigen (concise communication), 372
thyroid gland (correspondence), 514
Tularemia
levofloxacin treatment (correspondence), 167
oropharyngeal (continuing medical education), 637/654
Tumor necrosis factor-α (TNF-α), effects on neutrophil oxidative burst and β2-integrin expression, 125

Urinalysis, European guidelines, 173
Urinary tract infections
Norway, bacterial etiology and susceptibility, 543
nosocomial (editorial), 521
ESCMID Study Group reports, 523, 532
incidence, clinical characteristics and outcome (ESGNI-004 study), 532
persistent erythrovirus B19 infection in HIV-positive patient (concise communication), 507
microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study), 523

Vancomycin–cefpirome, methicillin-resistant *Staphylococcus aureus* (concise communication), 218
Vancomycin-intermediate *Staphylococcus aureus*, 267
Vancomycin-resistant *Enterococcus faecium* bacteremia, chlormaphenicol treatment, 17
Ventilator-associated pneumonia, Tarragona treatment strategy, 32
Vibrio alginolyticus acute gastroenteritis (correspondence), 104
Voriconazole-resistant *Aspergillus fumigatus*, 130

Yersinia plasmid-encoded outer protein antibodies in Hashimoto's thyroiditis, 138
Yersinia enterocolitica and *Yersinia pseudotuberculosis*, properties in red blood cell concentrate of different ABO groups during storage, 358

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 7, 718–723